Taken together, in this multi-cohort analysis, we confirmed the strong and robust mutual exclusivity between ESR1 and TP53 mutations in MBC, and this phenomenon is broadly observed in all ER+ MBC tumor types, while the rare occurrence of dual mutation-tumors is associated with unique clinical and genomic features. This evidence concerns the gene TP53 and neoplasm.